These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1616432)

  • 1. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness.
    Wang ET; Zhou DR; He LH
    Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Transdermal therapeutic system of scopolamine (TTS-S) in the prevention of sea sickness and its mechanism of action].
    Wang E
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1990 Oct; 25(5):299-302, 319. PubMed ID: 2076342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
    Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME; Royal JW; Shaw JE; Schmitt LG
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.
    Parrott AC
    Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus.
    Pyykkö I; Padoan S; Schalén L; Lyttkens L; Magnusson M; Henriksson NG
    Aviat Space Environ Med; 1985 Aug; 56(8):777-82. PubMed ID: 3929760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors.
    Gil A; Nachum Z; Dachir S; Chapman S; Levy A; Shupak A; Adir Y; Tal D
    Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1982 Aug; 53(8):770-2. PubMed ID: 7181807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of histaminergic drugs in experimental motion sickness.
    Matsnev EI; Sigaleva EE
    J Vestib Res; 2007; 17(5-6):313-21. PubMed ID: 18626141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of scopolamine and cyclizine on visual-vestibular interaction in humans.
    Gowans J; Matheson A; Darlington CL; Smith PF
    J Vestib Res; 2000; 10(2):87-92. PubMed ID: 10939683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visual and vestibular components of motion sickness.
    Eyeson-Annan M; Peterken C; Brown B; Atchison D
    Aviat Space Environ Med; 1996 Oct; 67(10):955-62. PubMed ID: 9025818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1981 Jun; 52(6):337-9. PubMed ID: 7259691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S; Shapira S; Zilbiger A; Ribak J
    Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of phenytoin in the prevention of motion sickness.
    Chelen W; Kabrisky M; Hatsell C; Morales R; Fix E; Scott M
    Aviat Space Environ Med; 1990 Nov; 61(11):1022-5. PubMed ID: 2256875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histaminergic and cholinergic neuron systems in the impairment of human thermoregulation during motion sickness.
    Nobel G; Tribukait A; Mekjavic IB; Eiken O
    Brain Res Bull; 2010 May; 82(3-4):193-200. PubMed ID: 20394809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of direction of head movement on motion sickness caused by Coriolis stimulation.
    Woodman PD; Griffin MJ
    Aviat Space Environ Med; 1997 Feb; 68(2):93-8. PubMed ID: 9125096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transderm scopolamine efficacy related to time of application prior to the onset of motion.
    Levy GD; Rapaport MH
    Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of low-dose intranasal scopolamine for motion sickness.
    Simmons RG; Phillips JB; Lojewski RA; Wang Z; Boyd JL; Putcha L
    Aviat Space Environ Med; 2010 Apr; 81(4):405-12. PubMed ID: 20377145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.